977-P: Multisensing Implantable Automated Insulin Delivery System—Expectations of Parents, People with Type 1 and Type 2 Diabetes

Introduction and Objective: A potential evolution of AID systems is the intraperitoneal route and consideration of ketones and lactate. The development of an implantable AID system with multi-metabolite sensing should consider the expectations of people with diabetes. Methods: In an online survey, parents of children with type 1 diabetes and adults with type 1 and type 2 diabetes were introduced to such a AID system. They were asked 1) how often they would still want to check the system, 2) the maximum number of daily input they may be required to make so that the AID is still perceived as unobtrusive, 3) how helpful and burdensome the constant access to lactate and ketones would be. Results: Data from 526 participants were analyzed (465 type 1, 44 type 2, 17 parents; all with CGM). Parents would check the AID 5.5±3.2 times/day, adults with type 1 diabetes 5.0±3.2 times and adults with type 2 diabetes 4.3±3.4 times (p=.12). The maximum daily user input was 4.1±2.5 for parents, 3.6±2.1 for type 1 and 3.0±1.7 for type 2 diabetes (p=.11). Perceived helpfulness and burden of lactate and ketone measurement was moderate, except for parents’ ratings of ketones (Figure; all p>.05). Conclusion: Perceptions towards an implantable AID system were comparable between the groups. A rather high amount of manual input would still be tolerated. More information on the helpfulness of lactate and ketones is needed. D. Ehrmann: Advisory Panel; Dexcom, Inc. Speaker's Bureau; Dexcom, Inc. Consultant; Roche Diabetes Care. Speaker's Bureau; Roche Diabetes Care, Sanofi, Eli Lilly and Company, Boehringer-Ingelheim. B. Kulzer: Advisory Panel; Abbott, Dexcom, Inc. Consultant; Becton, Dickinson and Company. Other Relationship; Insulet Corporation, AstraZeneca. Board Member; Sanofi-Aventis Deutschland GmbH. Advisory Panel; Roche Diabetes Care, Novo Nordisk. N. Hermanns: Advisory Panel; Dexcom, Inc., Abbott Diagnostics. Speaker's Bureau; Abbott Diagnostics. Advisory Panel; Roche Diabetes Care. Funded by the European Innovation Council (EIC) under grant agreement No. 101115233. The EIC receives support from the European Union?s Horizon Europe research and innovation programme.